LEO 138559
LEO Pharma,argenx
['leo 138559', 'atopic dermatitis ', 'derm', 'leo pharma']
leo pharma presents late-breaking positive phase 2a efficacy and safety results of leo 138559 in moderate-to-severe atopic dermatitis at the 2023 aad annual meeting 
Breaking news from Business Wire